Celcuity (NASDAQ:CELC) Stock Falls 5.9% – Here’s What Happened

Posted by George Bondi on Nov 13th, 2026

Shares of Celcuity, Inc. (NASDAQ:CELC – Get Free Report) fell 5.9% during trading on Wednesday. The stock traded as low as $66.37 and last traded at $66.2440. Approximately 25,517 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 1,146,762 shares. The stock had previously closed at $70.37.

Analyst Ratings Changes

Several brokerages have weighed in on CELC. Needham & Company LLC cut their price target on Celcuity from $140.00 to $134.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. JPMorgan Chase & Co. started coverage on Celcuity in a research note on Thursday, September 17th. They set an “overweight” rating and a $157.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research report on Monday. Finally, HC Wainwright dropped their target price on Celcuity from $155.00 to $150.00 and set a “buy” rating for the company in a research note on Monday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $151.79.

Get Our Latest Report on CELC

Celcuity Stock Performance

The company has a market cap of $3.15 billion, a price-to-earnings ratio of -13.62 and a beta of 0.16. The company has a current ratio of 14.62, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock’s 50 day moving average price is $73.11 and its 200 day moving average price is $98.49.

Celcuity (NASDAQ:CELC – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.30. On average, analysts expect that Celcuity, Inc. will post -5.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently made changes to their positions in the stock. Teachers Retirement System of The State of Kentucky grew its stake in shares of Celcuity by 39.9% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 17,729 shares of the company’s stock valued at $1,410,000 after buying an additional 5,053 shares during the period. ACT Capital Partners L.P. acquired a new stake in shares of Celcuity during the 3rd quarter worth $4,664,000. Nan Fung Trinity HK Ltd. raised its position in shares of Celcuity by 33.4% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 103,775 shares of the company’s stock worth $8,252,000 after buying an additional 25,975 shares during the period. Pictet Asset Management Holding SA raised its position in shares of Celcuity by 10,659.7% in the 3rd quarter. Pictet Asset Management Holding SA now owns 291,049 shares of the company’s stock worth $23,144,000 after buying an additional 288,344 shares during the period. Finally, Integrity Alliance LLC. raised its position in shares of Celcuity by 2.2% in the 3rd quarter. Integrity Alliance LLC. now owns 11,868 shares of the company’s stock worth $944,000 after buying an additional 250 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

(Get Free Report)

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.